BIOTECH CATALYST AI SCANNER — June WK2

The calendar does the heavy lifting this week. ENDO, EHA and the tail of ASCO converge in mid-June, stacking the kind of conference readouts that move small-cap biotech regardless of where the broad tape sits. Three of this week's featured names — Rezolute, MBX and Cellectis — present on the same day, June 13, and the spread of possible outcomes inside a single week is unusually wide: from de-risked, cash-rich data updates to penny-stock regulatory coin flips.

The bifurcation we flagged through the spring has only sharpened. On one side, deeply capitalized names — Celcuity, Candel, MBX, Larimar — head into catalysts with multi-year runways, presenting data they can afford to be patient about. On the other, a cluster of names is testing survival on the same release: BioAtla at roughly six weeks of cash, Gossamer at five months after a missed Phase 3, Actuate and Palatin running on fumes. For catalyst traders, the readout itself often matters less than the runway underneath it.

Thematically, three threads run through the featured list. Targeted oncology dominates — KRAS G12D (Verastem), pan-PI3K/mTOR (Celcuity), MEK (Pasithea), Nectin-4 (BioAtla) — a reminder that precision medicine is where catalyst density lives. Rare-disease replacement and hormone therapies (Rezolute in hyperinsulinism, MBX in hypoparathyroidism, Larimar in Friedreich's ataxia on the watchlist) offer cleaner regulatory paths. And cell-and-gene therapy keeps supplying binary drama, this week through Cellectis's allogeneic CD22 CAR-T.

What We're Tracking:

Trading Below Cash: GOSS, KTTA, RNA
Cash Pressure: VSTM, GOSS, QURE, AIM, ACTU, NMRA, PTN
Initial Data: RZLT, QURE, JBIO, ACTU, NMRA, PTN
Multi-Catalyst: CLLS

#1. RZLT — Rezolute Inc.

THE CATALYST
Event: Ersodetug (RZ358) — Phase 3 Topline Data in Congenital Hyperinsulinism
Date: Jun 13, 2026
FDA Status: BTD
BSI: 8.4/10

Rezolute walks into its ENDO readout with momentum already at its back — open-label extension data show patients holding glycemic control while weaning off standard drugs, a durability signal no competing glucagon analog has matched. The company works exclusively on hyperinsulinism-driven hypoglycemia across congenital and tumor settings, and licenses ersodetug worldwide from XOMA. FDA granted Breakthrough Therapy status for congenital HI in January 2025, and positive interim Phase 3 upLIFT data in tumor HI landed in May 2026.

📈 The Setup: Congenital hyperinsulinism has no targeted therapy — patients lean on diazoxide and octreotide, both decades old and poorly tolerated. Ersodetug (RZ358) is a fully human monoclonal antibody that binds the insulin receptor at an allosteric site and dials down the runaway insulin signaling that drives blood sugar dangerously low. In the Phase 3 sunRIZE trial (N=62) it cut time spent in hypoglycemia by more than 50% and weekly hypoglycemia events by roughly 50–80% versus placebo on continuous glucose monitoring, with the open-label extension showing patients sustaining that benefit while tapering background therapy. The closest competitor, Zealand's dasiglucagon, sits stalled behind two manufacturing-related FDA rejections despite decent efficacy — leaving the lane open. June 13 at ENDO is the full topline, and with RSI near 76, the bar for a clean beat is high but the setup is genuinely in front.

✅ The Edge: Breakthrough Therapy Designation plus an extension showing patients tapering off diazoxide and octreotide gives ersodetug something dasiglucagon never produced — durable, real-world control. Its insulin-receptor mechanism works across every HI subtype, not just one genetic flavor.
⚠️ The Risk: The congenital HI population is tiny and heterogeneous, and FDA has not set firm precedent on accepting CGM-based hypoglycemia metrics as a registration endpoint — the same agency that handed Zealand repeated rejections on its competing program.

#2. CELC — Celcuity Inc.

THE CATALYST
Event: Gedatolisib + Fulvestrant (VIKTORIA-1) — PDUFA Regulatory Decision in HR+/HER2- Advanced Breast Cancer
Date: Jul 17, 2026
FDA Status: BTD, FTD
BSI: 8.4/10

Celcuity goes into a July PDUFA holding something rare for a single-asset oncology company: pivotal data strong in both halves of its target population. The recently reported VIKTORIA-1 mutant-cohort results — gedatolisib roughly doubling progression-free survival over the current standard — open a second regulatory path on top of the wild-type indication already under review. The company licensed gedatolisib from Pfizer in 2021, upsized a convertible note offering in June, and is building commercial infrastructure while expanding into first-line via the VIKTORIA-2 trial.

📈 The Setup: HR+/HER2- breast cancer that progresses after CDK4/6 inhibitors splits into PIK3CA-mutant and wild-type camps, and most targeted drugs serve only one. Gedatolisib is an intravenous pan-PI3K/mTOR inhibitor — it shuts down every class I PI3K isoform plus both mTOR complexes rather than picking off a single mutation. In VIKTORIA-1, the mutant cohort on gedatolisib plus palbociclib and fulvestrant reached 11.1 months median PFS versus 5.6 for alpelisib (Piqray) plus fulvestrant (HR 0.50); the wild-type cohort already cleared the bar supporting the pending NDA. That breadth is the edge over isoform-selective rivals like alpelisib and the AKT inhibitor capivasertib. Curiously, the stock sold off into the catalyst — RSI 24, down a third in a month — pricing in approval risk the data don't obviously support. July 17 is the wild-type decision; the mutant sNDA follows behind it.

✅ The Edge: Gedatolisib is the only pan-PI3K/mTOR agent tested pivotally in both wild-type and mutant populations, delivering near-identical PFS gains in each — a dual-label opportunity from one trial that single-target alpelisib and capivasertib can't replicate.
⚠️ The Risk: Class toxicity is the soft spot: stomatitis and related PI3K/mTOR side effects could throttle uptake against entrenched alpelisib, and any grade 3+ imbalance in the mutant data could draw an FDA information request or advisory committee that slips the sNDA.

#3. VSTM — Verastem Inc.

THE CATALYST
Event: VS-7375 (GFH375) — Phase 1/2 Interim Data in KRAS G12D-Mutant Cancer
Date: Q2 2026 (Est.)
BSI: 8.0/10

Verastem is no longer purely pre-commercial — it sells the AVMAPKI plus FAKZYNJA co-pack for recurrent low-grade serous ovarian cancer, which gives it revenue most of its micro-cap peers lack. The catalyst here, though, is VS-7375, licensed from China's GenFleet for territories outside greater China in early 2025. FDA granted Fast Track for KRAS G12D-mutant pancreatic cancer in July 2025, and the US Phase 1/2 trial opened a month earlier. The Needham, Massachusetts company runs both RAS/MAPK programs in parallel.

📈 The Setup: There is no approved drug for KRAS G12D — the most common KRAS mutation in pancreatic cancer — so this is open territory. VS-7375 is an oral inhibitor that binds KRAS G12D in both its active and inactive states (an "ON/OFF" approach), aiming for deeper, more durable suppression than rivals that hit only one state. The read on the data so far comes from partner GenFleet's China trial: a 40.7% response rate and 92.2% four-month survival in heavily pretreated pancreatic patients at 600 mg, plus 68.8% response in a small lung-cancer cohort. The US trial has pushed to 1200 mg with no new safety flags. The catch is competitive — Revolution Medicines' pan-RAS daraxonrasib is further along in Phase 2/3 and covers more mutations. This 1H interim is an early look, not a pivotal, and at roughly eight months of runway, expectations are doing a lot of work.

✅ The Edge: Dual ON/OFF binding is VS-7375's pitch for going deeper than single-state rivals, and the China dataset already set a credible 40–69% response benchmark at the same doses now being tested in the US — a head start no other G12D-selective agent has shown in pancreatic cancer.
⚠️ The Risk: The space is filling fast with broader pan-RAS drugs — Revolution's daraxonrasib chief among them — that could define the efficacy bar before VS-7375 reaches registration, and FDA typically wants randomized survival data, not single-arm response rates, for full approval.

#4. GOSS — Gossamer Bio Inc.

THE CATALYST
Event: Seralutinib (GB002) — Pre-NDA FDA Meeting in Pulmonary Arterial Hypertension
Date: Jun 15, 2026
BSI: 8.0/10

Gossamer is down to a binary regulatory question after seralutinib narrowly missed its Phase 3 primary endpoint in February. What keeps it interesting is the structure around it: a May 2024 Chiesi collaboration carrying $160 million in development reimbursement plus milestones and royalties, and an option on Respira Therapeutics' inhaled vardenafil candidate. The San Diego firm has since upgraded from a Type C to an in-person Pre-NDA Type B meeting — a signal FDA is at least willing to discuss a filing path.

📈 The Setup: Pulmonary arterial hypertension just got a new anchor in Merck's Winrevair (sotatercept), the first approved activin-signaling inhibitor, so any newcomer needs a distinct angle. Seralutinib is an inhaled small-molecule that blocks PDGFR, CSF1R and c-KIT — kinases tied to the vascular remodeling that scars pulmonary arteries — and its local lung delivery sets it apart from oral and infused therapies. The problem is the data: Phase 3 PROSERA delivered a placebo-adjusted +13.3 meters on six-minute walk distance at week 24, but at p=0.0320 it missed the prespecified 0.025 threshold. Secondary, imaging and safety signals were supportive. At eighteen cents a share and a market cap below its cash, the stock prices in failure-to-file; the June 15 meeting is the entire thesis — whether FDA accepts a totality-of-evidence NDA or demands another trial Gossamer can't fund on five months of runway.

✅ The Edge: Seralutinib is the only inhaled tyrosine-kinase inhibitor in registrational PAH development, and the Chiesi deal funds global work regardless — so a constructive FDA meeting could greenlight a September filing without Gossamer footing the bill or diluting immediately.
⚠️ The Risk: The cleanest read on PROSERA is that it missed. If FDA treats the regional placebo-response discrepancies and the failed primary as grounds for a confirmatory trial, the timeline blows past the cash runway — and a sub-$50M company has little leverage to negotiate.

#5. BCAB — BioAtla Inc.

BioAtla's board kicked off a formal strategic review in March 2026 — asset sales, licensing, partnerships all on the table — which tells you where the company sits: a sub-$6 million market cap with weeks of cash, exploring exits. It develops Conditionally Active Biologic antibodies that switch on only in the acidic tumor microenvironment, and holds a worldwide license deal with Context Therapeutics worth up to $133.5 million for a Nectin-4 x CD3 bispecific. An SPV financing is keeping its Oz-V program alive.

#6. CADL — Candel Therapeutics Inc.

THE CATALYST
Event: CAN-2409 (aglatimagene besadenovec) — Phase 3 Interim Data in Localized Prostate Cancer
Date: Q2 2026 (Est.)
FDA Status: FTD, RMAT
BSI: 7.5/10

Candel enters its Q2 readout from a position most catalyst names never reach: pivotal Phase 3 CAN-2409 data already published in The Lancet Oncology, and a balance sheet — bolstered by a $100 million raise paired with an RTW Investments royalty deal — that funds BLA preparation without near-term dilution. The Needham, Massachusetts company builds viral immunotherapies for solid tumors and has lined up commercial partners (EVERSANA for US launch, IDEA Pharma for strategy) ahead of a planned filing.

📈 The Setup: Localized prostate cancer at intermediate-to-high risk is treated with radiation, sometimes plus hormone therapy, and no immunotherapy has broken into the setting. CAN-2409 is an adenoviral vector carrying the herpes thymidine kinase gene; paired with the antiviral prodrug valacyclovir, it kills tumor cells in a way that provokes a systemic immune response (immunogenic cell death). Added to radiotherapy in the pivotal trial (n=745), it cut the risk of recurrence or death by 30% on disease-free survival (HR 0.70, p=0.0155), and at a median 58 months the prostate-cancer-specific benefit deepened to HR 0.61. The trial ran under a Special Protocol Assessment with FDA, with Fast Track and RMAT designations in hand. The Q2 interim and a Q3 biomarker readout are de-risking steps toward a late-2026 BLA — this is a cash-rich company executing, not a binary coin flip.

✅ The Edge: An SPA-agreed pivotal design, RMAT and Fast Track designations, and DFS benefit holding out to 58 months give CAN-2409 a regulatory package no competing localized-prostate immunotherapy can match — there are no direct Phase 3 rivals in the setting.
⚠️ The Risk: FDA has little precedent accepting disease-free survival as the sole basis for approval in a cancer where men rarely die near-term; the agency could ask for overall-survival maturation despite the SPA, stretching the timeline and the launch economics.

#7. QURE — uniQure N.V.

THE CATALYST
Event: AMT-162 — Phase 1 Initial Data in SOD1-ALS
Date: Q2 2026 (Est.) — program discontinued; see below
BSI: 7.4/10

This is the cautionary entry in the week's list. uniQure halted its AMT-162 gene therapy in 2025 after a dose-limiting toxicity in the second dose cohort triggered an independent monitoring-committee review — only five patients were ever dosed, and no further dosing or data readout is planned. The company's broader focus remains AAV-based therapies for rare neurological and metabolic disease, and its lead value now sits with AMT-130 in Huntington's, where FDA has asked for a randomized Phase 3.

📈 The Setup: AMT-162 was a one-time intrathecal gene therapy — an AAVrh10 vector delivering microRNA to silence the mutant SOD1 gene behind this form of ALS — pitched as a single-dose alternative to Biogen and Ionis's approved Qalsody (tofersen), an antisense drug that requires chronic spinal infusions. The appeal was obvious: dose once, knock down the toxic protein for good. The EPISOD1 trial got five patients in before a serious adverse event classified as dose-limiting stopped it, with no efficacy signal strong enough to justify pushing on. Whatever the scanner's catalyst feed still shows, there is no live readout here. Tofersen keeps the SOD1-ALS field to itself, and uniQure's $1.8 billion market cap now rests almost entirely on the Huntington's program — not on anything coming out of this terminated study.

✅ The Edge: The only residual upside is incidental — long-term safety follow-up on the five dosed patients could surface a clean biomarker signal that keeps the miRNA platform partnerable. That is a thin thread, and it isn't the reason to own uniQure; AMT-130 in Huntington's is.
⚠️ The Risk: The risk is already realized — the program is discontinued. Treating the stale Q2 "initial data" line as a tradable catalyst would be a mistake: there is no dataset coming, and any residual ALS optionality here is gone.

#8. KTTA — Pasithea Therapeutics Corp.

THE CATALYST
Event: PAS-004 — Phase 1 Interim Data in MAPK-Driven Solid Tumors
Date: Q2 2026 (Est.)
BSI: 7.4/10

Pasithea trades below the cash on its books — a $21 million market cap against a balance sheet refilled by a $60 million December raise led by Vivo Capital and Janus Henderson. That negative enterprise value is the whole underdog pitch. The Miami Beach company is developing PAS-004, a once-daily oral MEK inhibitor, in parallel for NF1-associated plexiform neurofibromas (which earned Fast Track and Rare Pediatric Disease designations in 2026) and MAPK-driven solid tumors. A new chief medical officer came aboard alongside the financing.

📈 The Setup: NF1 nerve-sheath tumors already have two approved MEK inhibitors — selumetinib (Koselugo) and mirdametinib (Gomekli) — but both carry meaningful toxicity and only modest response rates, leaving room on tolerability. PAS-004 is a macrocyclic MEK1/2 inhibitor (it blocks the enzyme that activates ERK in the cancer-growth MAPK pathway), engineered for a long ~70-hour half-life and flatter drug exposure than the shorter-acting approved agents. The clinical evidence is still thin: the standout is a single BRAF-V600E melanoma patient who reached a confirmed partial response at just 15 mg and stayed on treatment past 11 months after failing prior MEK plus BRAF therapy. Dose escalation has climbed through 37 mg with clean pharmacokinetics and no dose-limiting toxicities. The Q2 update extends that to higher cohorts — useful safety and PK reads, but a long way from proof this beats the incumbents.

✅ The Edge: The differentiation is exposure, not yet efficacy: a ~70-hour half-life and tight peak-to-trough ratio could deliver steadier pathway suppression and fewer of the rash-and-retinopathy toxicities that dog selumetinib and mirdametinib — and the lone durable response after prior MEK/BRAF failure hints the molecule can work where others quit.
⚠️ The Risk: The data underneath this are minimal — one anecdotal response and a dose-escalation safety story. MEK inhibitors have repeatedly failed to separate from selumetinib in NF1, and a Q2 readout of PK and tolerability won't resolve whether PAS-004 actually clears that bar.

#9. MBX — MBX Biosciences Inc.

THE CATALYST
Event: Canvuparatide (MBX 2109) — Phase 2 Conference Presentation in Hypoparathyroidism
Date: Jun 13, 2026
BSI: 7.2/10

MBX cleared its End-of-Phase 2 meeting with FDA in March and has a green light to start Phase 3 in Q3 2026 — so the ENDO presentation on June 13 is a look at known-good data rather than a make-or-break readout. The Carmel, Indiana company designs precision peptides for endocrine and metabolic disease, with canvuparatide for hypoparathyroidism out front and two shots behind it: an obesity peptide in Phase 1 and a post-bariatric-hypoglycemia candidate in Phase 2. A 2025 upsized offering funds all of it.

📈 The Setup: Chronic hypoparathyroidism only recently got a dedicated replacement therapy in Ascendis's once-daily Yorvipath (palopegteriparatide), and that daily-injection bar is what canvuparatide is built to undercut. It's a long-acting PTH prodrug designed to release parathyroid hormone steadily for a full week from one subcutaneous shot — continuous, infusion-like exposure without the daily needle. In the Phase 2 Avail trial it hit the primary composite endpoint with 63% of patients responding versus 31% on placebo (p=0.042), climbing to 79% responders at six months in the extension; every patient finished the 12-week study, 94% rolled into the extension, none needed rescue therapy, and bone and kidney markers improved. ENDO adds the full durability picture. Rivals eneboparatide and encaleret are in Phase 3, but none offers weekly dosing — and with 63 months of runway, MBX trades on execution, not survival.

✅ The Edge: Canvuparatide is the only once-weekly PTH replacement in late-stage development; against Yorvipath's daily injection and the daily Phase 3 contenders eneboparatide and encaleret, a true weekly shot with a 94% extension opt-in rate is a concrete convenience advantage, not a marketing line.
⚠️ The Risk: Weekly dosing is also the exposure risk — a long-acting prodrug could surface immunogenicity or bone-turnover problems a small Phase 2 wouldn't catch, and Yorvipath's established daily calcium control sets a high bar for Phase 3 to match.

#10. CLLS — Cellectis S.A.

THE CATALYST
Event: UCART22 (BALLI-01) — Phase 1 Conference Presentation in Relapsed/Refractory B-ALL
Date: Jun 13, 2026
FDA Status: ODD
Additional catalysts: 1 more (Phase 1/2 data, 4Q 2026)
BSI: 7.2/10

AstraZeneca's 44% equity stake is the fact that frames Cellectis — a Paris-based gene-editing pioneer that, alongside the 2024 investment, runs a multi-target collaboration with AZ and retains a legacy Servier/Allogene license on its CD19 work. The company has built out its own US and European manufacturing for allogeneic, off-the-shelf CAR-T. Two catalysts sit within range, led by the BALLI-01 dataset at EHA on June 13.

📈 The Setup: Relapsed B-cell ALL patients who fail an approved CD19 CAR-T like Kymriah or Tecartus — often because the cancer drops the CD19 target — have few options left. UCART22 is Cellectis's answer: an off-the-shelf, donor-derived CAR-T engineered to hit CD22 instead, so antigen loss at CD19 doesn't render it useless. Phase 1 BALLI-01 has shown a 68% overall response rate with the company's second-generation ("Process 2") manufacturing in heavily pretreated patients, including some who'd already failed autologous CD19 therapy, with earlier cohorts reaching MRD-negative remissions lasting months. The EHA presentation details those responses in the post-CD19 population specifically. The competitive knock is real — Allogene's allogeneic CD19 cema-cel is further along, and bispecifics like blinatumomab already serve this market — and a Phase 1 update is a signal, not a pivotal. With essentially no runway left on the balance sheet, the AZ relationship is doing the heavy lifting.

✅ The Edge: CD22 targeting is the specific advantage — it addresses exactly the CD19 antigen-loss escape that limits the approved autologous CAR-Ts, in an off-the-shelf format that skips per-patient manufacturing, a niche Allogene's CD19-directed cema-cel doesn't cover.
⚠️ The Risk: Allogeneic CAR-T still has to prove its responses last as long as autologous; with reported runway essentially exhausted, Cellectis leans on AstraZeneca, and a small Phase 1 cohort won't on its own resolve durability or the rejection-and-safety questions FDA scrutinizes for donor-derived cells.

WATCHLIST

#11. JBIO — Jade Biosciences Inc. [IgA Nephropathy]

Price: $17.74 | Cap: $875.64M | Cash: $443.64M | RSI: 18.8 | Momentum: -29.4%
JADE-001 — Phase 1 Interim Data in IgA Nephropathy (Q2 2026 (Est.))
BSI: 7.4/10

The Intel: JADE-001 blocks APRIL (a cytokine that keeps IgA-producing B cells alive), aiming to shrink the antibody deposits that inflame the kidney in IgA nephropathy. Jade's pitch is an engineered half-life allowing less frequent dosing than rival APRIL antibodies like Otsuka's sibeprenlimab and Novartis's zigakibart. But this is a first-in-human Phase 1 interim — a deep cash position ($443M, 55-month runway) buys patience, while the clinical evidence is still essentially nonexistent.

#12. AIM — AIM ImmunoTech Inc. [Pancreatic Cancer]

Price: $0.5913 | Cap: $9.76M | Cash: $6.29M | RSI: 62.2 | Momentum: +22.9%
Ampligen (rintatolimod) + Imfinzi (durvalumab) — Phase 1/2 Interim Data in Pancreatic Cancer (Mid-2026 (Est.))
BSI: 7.2/10

The Intel: Ampligen (a TLR3 agonist that switches on innate antiviral immunity) plus AstraZeneca's durvalumab tries to turn "cold" pancreatic tumors hot enough for checkpoint blockade to work — a graveyard indication where PD-L1 drugs have repeatedly failed alone. The DURIPANC interim is early, the company carries under $7M in cash, and the competitive bar (FOLFIRINOX chemotherapy) is unforgiving. Interesting mechanism, brutal binary math.

#13. LRMR — Larimar Therapeutics Inc. [Friedreich's Ataxia]

Price: $3.29 | Cap: $341.77M | Cash: $267.67M | RSI: 31.7 | Momentum: -20.7%
Nomlabofusp (CTI-1601) — BLA Filing Submission in Friedreich's Ataxia (Q2 2026 (Est.))
FDA Status: BTD, ODD
BSI: 7.2/10

The Intel: Nomlabofusp delivers recombinant frataxin straight to mitochondria, replacing the protein Friedreich's ataxia patients can't make — the first frataxin-replacement approach to reach a BLA, where Phase 2 already showed dose-dependent tissue uptake. The only approved option, Biogen's Skyclarys (omaveloxolone), treats downstream oxidative stress rather than the root deficiency. Breakthrough and Orphan tags plus 18 months of cash support the filing; the open question is whether biomarker gains translate into function.

#14. ACTU — Actuate Therapeutics Inc. [Pancreatic Cancer]

Price: $1.94 | Cap: $46.42M | Cash: $4.45M | RSI: 16.2 | Momentum: -35.1%
Elraglusib + FOLFIRINOX + Losartan — Phase 2 Data in Metastatic Pancreatic Cancer (Q2 2026 (Est.))
BSI: 7.0/10

The Intel: Elraglusib (a GSK-3β inhibitor that blocks tumor survival pathways) is stacked on FOLFIRINOX chemotherapy and the stroma-loosening blood-pressure drug losartan in first-line metastatic pancreatic cancer. With under three months of cash and deeply negative momentum, Actuate faces maximum binary pressure — the triplet has to show clear separation from FOLFIRINOX alone, the same standard that has buried most pancreatic combinations. Thin data, thinner balance sheet.

#15. LIXT — Lixte Biotechnology Holdings Inc. [Ovarian Cancer]

Price: $7.00 | Cap: $86.68M | Cash: $18.47M | RSI: 68.6 | Momentum: +59.1%
LB-100 + Doxorubicin — Phase 1/2 Initial Data in Ovarian Clear Cell Carcinoma (Q2 2026 (Est.))
BSI: 6.9/10

The Intel: LB-100 inhibits PP2A (a phosphatase that helps cancer cells survive DNA damage), trying to resensitize ovarian clear cell carcinoma — a notoriously chemo-resistant subtype — to doxorubicin. The supporting evidence is still preclinical, so this initial clinical readout is genuinely first-look, yet the stock has run hard (RSI 69, +59% in a month). With 30 months of runway and a low float amplifying the move, the science sits early relative to the share-price enthusiasm.

#16. LYEL — Lyell Immunopharma Inc. [Colorectal Cancer]

Price: $13.05 | Cap: $304.51M | Cash: $225.78M | RSI: 24.1 | Momentum: -37.4%
LYL273 (GCC19CART) — Phase 1 Data in Metastatic Colorectal Cancer (Q2 2026 (Est.))
BSI: 6.9/10

The Intel: LYL273 is a CAR-T aimed at guanylyl cyclase C, a surface marker on colorectal cancer cells, with Lyell's gene-reprogramming meant to keep engineered T cells durable inside solid tumors — the wall that has stopped CAR-T outside blood cancers. Cash is solid ($226M, 17-month runway), but the data are minimal and solid-tumor CAR-T has a long history of early promise fading. A contrarian, oversold setup more than a proven one.

#17. RNA — Avidity Biosciences, Inc. [FSHD]

Price: $12.30 | Cap: $210.40M | Cash: $259.96M | RSI: 32.0 | Momentum: -6.0%
Delpacibart braxlosiran (del-brax) — BLA Filing Submission in Facioscapulohumeral Muscular Dystrophy (Q2 2026 (Est.))
FDA Status: FTD, ODD
BSI: 6.8/10

The Intel: Del-brax (delpacibart braxlosiran) is an antibody-oligonucleotide conjugate that ships siRNA into muscle to silence DUX4, the toxic gene behind facioscapulohumeral muscular dystrophy — the first targeted approach in a disease with no approved therapy. The FORTITUDE trial showed DUX4-biomarker reduction, and the company is trading below cash heading into a BLA filing. Fast Track and Orphan designations plus genuinely strong competitive positioning make this the watchlist's most de-risked name.

#18. SPRO — Spero Therapeutics Inc. [Complicated UTI]

Price: $2.98 | Cap: $172.55M | Cash: $67.76M | RSI: 62.2 | Momentum: +17.8%
Tebipenem HBr (SPR994) — PDUFA Regulatory Decision in Complicated UTI / Pyelonephritis (Jun 18, 2026)
BSI: 6.7/10

The Intel: Tebipenem HBr would be the first oral carbapenem (a broad-spectrum antibiotic that blocks bacterial cell-wall building) for complicated UTIs and pyelonephritis, letting patients skip IV therapy — Phase 3 PIVOT-PO was positive and a PDUFA lands June 18. The convenience case is strong; the commercial one is harder, given how cheap and entrenched existing IV and oral antibiotics are. A high-quality regulatory catalyst with modest differentiation economics.

#19. NMRA — Neumora Therapeutics Inc. [Major Depressive Disorder]

Price: $1.75 | Cap: $324.25M | Cash: $113.04M | RSI: 33.8 | Momentum: -24.9%
Navacaprant (NMRA-140) — Phase 3 Topline Data in Major Depressive Disorder (Q2 2026 (Est.))
BSI: 6.7/10

The Intel: Navacaprant is a kappa opioid receptor antagonist (it blocks brain receptors tied to stress and low mood) targeting anhedonia, the pleasure-loss symptom standard SSRIs handle poorly. The catch: an earlier KOASTAL-1 Phase 3 readout disappointed, so any new topline faces deep skepticism and has to show clean separation from placebo. With seven months of cash and the bar set by entrenched generic antidepressants, this is a show-me readout.

#20. PTN — Palatin Technologies Inc. [Erectile Dysfunction]

Price: $14.34 | Cap: $25.51M | Cash: $6.92M | RSI: 45.9 | Momentum: -24.5%
Bremelanotide + PDE5i — Phase 3 Topline Data in Erectile Dysfunction (Q2 2026 (Est.))
BSI: 6.7/10

The Intel: Palatin pairs bremelanotide (a melanocortin activator that works centrally on arousal) with a PDE5 inhibitor like Viagra to rescue men those vasodilators don't help — a central-plus-vascular combination. But the competitive math is brutal: PDE5 inhibitors are genericized and cheap, commercial prospects are weak, and Palatin runs a micro float on under five months of cash into a Phase 3 topline. High-volatility binary.

The Strategist's Take

If you want quality over lottery tickets this week, the top of the board earns it. Celcuity (BSI 8.4) is the standout — pivotal data strong in both PIK3CA-mutant and wild-type breast cancer, a July PDUFA, and a stock that sold off into the catalyst for reasons the data don't obviously justify. Candel (7.5) and MBX (7.2) are the patient-money names: published or EOP2-cleared data, FDA designations, multi-year runways, and catalysts that de-risk rather than make-or-break. Rezolute (8.4) tops the ranking on genuine merit — Breakthrough status and durable extension data — though RSI near 76 means much of the good news is already in the price.

A word on calibration. These BSI scores carry a +1.00 manual adjustment this week, and it flatters the bottom of the featured list more than the fundamentals warrant. Gossamer at a calibrated 8.0 is the clearest example: a company that missed its Phase 3 primary endpoint, trades at eighteen cents, and is betting everything on whether FDA lets it file off a totality-of-evidence argument. Read that as a deep-value regulatory gamble, not a top-decile setup. The same caution applies to Verastem (8.0), where the competitive position against Revolution Medicines' pan-RAS franchise is the soft spot, and to micro-cap BioAtla (7.5), where six weeks of cash and a strategic review matter more than the response rates.

And one correction the ranking demands: uniQure (#7, calibrated 7.4) is on the list because of a stale catalyst feed — its AMT-162 ALS program was discontinued in 2025 after a dose-limiting toxicity, only five patients dosed, with no readout coming. There is no live event there; the company's value sits with AMT-130 in Huntington's. Don't trade the headline. As always, the ranking is a screen, not a recommendation — the conference calendar makes June 13 the week's center of gravity, but cash runway tells you who can survive a miss.

About This Scanner

This weekly report identifies biotech catalyst opportunities using quantitative screening combined with fundamental analysis.

What the Score Means: The BSI Score (0-10) reflects overall opportunity quality based on technical setup and fundamental characteristics. Higher scores indicate more favorable setups; lower scores indicate elevated uncertainty. This is NOT a prediction of catalyst outcomes or stock direction. Scores in this issue include a +1.00 manual calibration adjustment.

Data Sources: Financial data from market feeds and regulatory filings. Catalyst dates are estimates based on company guidance and subject to change.

Important: This report is for informational and educational purposes only. It does not constitute investment, financial, or medical advice. Conduct your own due diligence before making investment decisions.

Disclaimer

The information provided is for informational purposes only and should not be construed as financial, investment, legal, or professional advice.

Key Risks:

Clinical trials: Most drug candidates fail in development
Regulatory: FDA decisions remain unpredictable
Financing: Companies may dilute at any time
Volatility: Small-cap biotech stocks experience extreme price swings

Past performance does not guarantee future results.

Scanner Version: 3.2 | Generated: 2026-06-05T08:36:04.838071